Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis

Larry Beresford  |  Issue: May 2019  |  

Larry Beresford is a medical journalist in Oakland, Calif.

References

  1. McMahan ZH, Paik JJ, Wigley FM, et al. Determining the risk factors and clinical features associated with severe gastrointestinal dysmotility in systemic sclerosis. Arthritis Care Res (Hoboken). 2018 Sep;70(9):1385–1392.
  2. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000 Nov;43(11):2437–2444.
  3. Baron M, Hudson M, Steele R, et al. Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol. 2011 Sep;38(9):1925–1930.

Related Articles

    Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on Management

    McMahan et al. examined how abnormal gastrointestinal (GI) transit may contribute to GI severity and symptoms in patients with systemic sclerosis (SSc). About 90% of people with SSc have GI tract involvement, and understanding the connection between GI symptoms, their severity and abnormal GI transit may permit targeted therapeutic approaches for these patients.

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Targeted Therapy for Scleroderma Fibrosis

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…